Similarly, 20% of NAFLD patients were on SGLT2 inhibitors compared to 35% in the non-NAFLD group (p = 0.042), suggesting a protective effect of these agents. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.